CLA	cutaneous lymphocyte-associated antigen
CT	computer tomography
CTLA-4	cytotoxic T-lymphocyte-associated protein 4
cutAE	cutaneous immune-related adverse event
DMSO	dimethylsulfoxide
EDTA	ethylenediaminetetraacetic acid
FCS	fetal calf plasma
ICI	immune checkpoint inhibition
irAE	immune-related adverse event
NK	natural killer cell
NR	non-responder
NSCLC	non-small cell lung cancer
PBMC	peripheral blood mononuclear cell
PBS	phosphate-buffered saline
PD1	programmed cell death protein 1
PET	positron emission tomography
PFS	progression-free survival
R	responder
RECIST	response evaluation criteria in solid tumors